Legato Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Legato Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Buy	161,460 +39,509	+32%	+$358K	0.13%	235
2026 Q1	$1.03M	Sell	121,951 -1,698	-1%	-$16.2K	0.09%	291
2025 Q4	$1.5M	Buy	123,649 +10,829	+10%	+$132K	0.13%	245
2025 Q3	$1.32M	Hold	112,820	–	–	0.14%	222
2025 Q2	$1.05M	Sell	112,820 -270	-0.2%	-$2.11K	0.12%	260
2025 Q1	$829K	Sell	113,090 -1,730	-2%	-$13.3K	0.11%	303
2024 Q4	$981K	Sell	114,820 -34,695	-23%	-$338K	0.13%	303
2024 Q3	$1.3M	Hold	149,515	–	–	0.16%	225
2024 Q2	$1.02M	Hold	149,515	–	–	0.14%	252
2024 Q1	$1.36M	Hold	149,515	–	–	0.16%	205
2023 Q4	$667K	Buy	+149,515	New	+$442K	0.09%	353
2023 Q3	–	Sell	-116,389	Closed	-$601K	–	615
2023 Q2	$601K	Buy	+116,389	New	+$692K	0.08%	383

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Legato Capital Management's OCUL Position: Q2 2026 in Review

Legato Capital Management increased its Ocular Therapeutix (OCUL) stake by 32% in Q2 2026, buying an estimated $358K and bringing the position to 161,460 shares worth $1.59M. The position accounts for 0.13% of the portfolio, ranked #235.

Legato Capital Management first reported a position in OCUL in Q2 2023 and has held it in 12 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Legato Capital Management held 161,460 shares of Ocular Therapeutix worth $1.59M as of Q2 2026.
Legato Capital Management bought 39,509 Ocular Therapeutix shares in Q2 2026, an estimated $358K.
Ocular Therapeutix made up 0.13% of Legato Capital Management's portfolio in Q2 2026, its #235 holding.
Legato Capital Management first reported a position in Ocular Therapeutix in Q2 2023 and has held it in 12 quarters since.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.